Targovax presented ONCOS-102 poster at 13th International Adenovirus Meeting

Oslo, Norway, 1 October 2018: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company presented at the following conference: 13th International Adenovirus Meeting Date: 27 September 2018 Presenter: Lukasz Kuryk, Director Clinical Science Poster session: 20:00 – 23:00 Venue: San José Vista Hermosa, Mexico Abstract title: “ Anti-tumor specific T-cell responses induced by oncolytic adenovirus ONCOS-102 in peritoneal mesothelioma mouse model ” Please see the poster below: 1809 Poster ONCOS-102 For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: [email protected] Media and IR enquires: Andreas Tinglum – Corporate Communications (Norway) Phone: +47 9300 1773 Email: [email protected] Simon Conway/Stephanie Cuthbert – FTI Consulting (International) Phone: +44 20 3727 1000 Email: [email protected] About Targovax Activating the patient’s immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It activates the immune system to generate tumor-specific immune responses. In a phase I monotherapy trial, ONCOS-102 induced both local and systemic innate and adaptive immune activation, with associated clinical benefit. In an ongoing phase I trial, patients who have progressed on anti-PD1 checkpoint inhibitors and treated with ONCOS-102 in combination with Keytruda, demonstrated responses in three of nine patients (33% ORR) including one complete response. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial expected to report around new year 2019-20.

The release as fetched from its publisher. circio.com ↗